Latest Headlines

Latest Headlines

Analyst: Mitsubishi Tanabe's tobacco-based flu jab could have 'significant impact' on market

Following Mitsubishi Tanabe's announcement that its tobacco-based flu vaccine could hit the market by 2018 or 2019, a GlobalData analyst has lauded the Japanese company's candidate as poised to "take over" the flu vaccine market from traditional egg-based vaccines.

Chinese researchers warn H1N1 swine flu has 'pandemic threat' potential

Researchers at China's National Avian Influenza Reference Laboratory are warning that the family of Eurasian avian-like H1N1 swine viruses have acquired the ability to infect humans and "pose the highest pandemic threat" to mankind.

Second flu shot helps cancer patients stave off infection, Yale team says

A team from the Yale Cancer Center has devised a novel dosing schedule for flu vaccines aimed at increasing protection for cancer patients who are at a higher risk of contracting the viral infection.

Cepheid nabs FDA OK for point-of-care flu test

Just in time for peak flu season, Cepheid got an FDA nod for its rapid influenza and RSV test for doctors' offices, giving the company some added momentum as it prepares to launch its point-of-care molecular diagnostic device.

Japan's Mitsubishi Tanabe plans big push in U.S. sales

Japan's Mitsubishi Tanabe Pharma plans to spend more than $1.6 billion as part of a "medium-term business plan" to grow its new-drug sales in the United States and may use mergers and acquisitions to expand its footprint there.

WHO meeting could change strain selection for flu vaccines

Health officials and experts will discuss ways to improve global surveillance of the flu and expedite the selection process for which flu strains to include in the vaccine each year.

J&J;, Scripps Research Institute test 'universal' flu vaccine in mice, monkeys

The NIAID may have posted 94% efficacy in mice for its investigational "universal" flu vaccine, but The Scripps Research Institute and partner Johnson & Johnson are hot on its heels.

CSL reports record $1.4B profit following Novartis flu vaccine purchase

CSL is now the second largest flu vaccine manufacturer in the world, thanks to its acquisition of Novartis' flu vaccine business. The company reported a AU$1.9 billion ($1.4 billion) full-year profit, a 6% increase over the previous year.

Novavax reports PhII success for quadrivalent seasonal flu vax

Novavax is making waves in the influenza space, reporting positive Phase II results for its quadrivalent seasonal flu vaccine on Thursday.

NIAID scientists one step closer to 'universal' flu vaccine

A vaccine against a wide range of flu viruses has long eluded scientists, but NIAID researchers have discovered what could be the foundation of a 'universal' flu vaccine.
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • next ›
  • last »